Lercanidipine hydrochloride

CLINICAL USE

Calcium-channel antagonist:Mild to moderate hypertension

DOSE IN NORMAL RENAL FUNCTION

10 to 20 : mg daily

PHARMACOKINETICS

Molecular weight :648.2

%Protein binding :>98

%Excreted unchanged in urine : 50 (as metabolites)

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :8–10/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Use small doses and titrate to response

10 to 20 : Use small doses and titrate to response

<10 : Use small doses and titrate to response

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HD :Unlikely to be dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Antibacterials: avoid concomitant use with erythromycin

Anti-epileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone

Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole – avoid concomitant useAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers

Antivirals: concentration increased by ritonavir – avoid concomitant useCardiac glycosides: digoxin concentration increased

Ciclosporin: concentration of both drugs may be increased – avoid concomitant use

Grapefruit juice: concentration increased – avoid concomitant useTheophylline: possibly increased theophylline concentration

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

Take before food

OTHER INFORMATION

Causes less peripheral oedema than other calcium-channel blockersLercanidipine hydrochloride.426 LETroZoLELetrozole

CLINICAL USE

Treatment of advanced breast cancer

DOSE IN NORMAL RENAL FUNCTION

2.5 mg daily

PHARMACOKINETICS

Molecular weight :285.3

%Protein binding :60

%Excreted unchanged in urine : 6

Volume of distribution (L/kg) :1.87

half-life – normal/ESRD (hrs) :48/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Probably dialysed. Use with caution

HD :Dialysed. Use with caution

HDF/high flux :Dialysed. Use with caution

CAV/VVHD :Probably dialysed. Use with caution